|Articles|October 18, 2021
TD2 and Medidata Partner in ClinOps
Advertisement
Medidata, a Dassault Systèmes company, has announced that Translational Drug Development (TD2), a precision oncology contract research organization, has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions, offerings within Medidata’s Unified Platform.
Rave CTMS aims to address struggles that study teams experience in trying to manage and oversee clinical trials due to the fragmented and rapidly changing trial ecosystem. In 2021, Medidata released enhancements to Rave CTMS including ad hoc reporting and proactive risk management support.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Workforce Compression in AI-Driven Clinical Trial Operations
2
From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting
3
Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First
4
Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology
5